TrialJAMA oncology2020

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

I-SPY2 Trial Consortium et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.